Background: Tolvaptan therapy has been established as an effective therapy for patients with heart failure. However, it is still unclear whether tolvaptan therapy is effective even in elderly patients or not. In this study, we investigate efficacy of tolvaptan in elderly patients with severe heart failure. Methods: Between April 2015 and March 2016, 36 patients(15 male and 21 female) with over eighties(87.6 ± 44.0 years old) and severe heart failure were treated with tolvaptan. Results: Except for 8 patinets died during hospitalization, 28 patients improved heart failure and discharged. There were no patients discontinued tolvaptan due to adverse effect. In 22 patients (11 male and 11 female, 87.4 ± 4.1 years old) continued tolvaptan after discharge, 10 patients died, 6 patients were hospitalized with heart failure, and only 6 patients were event free. Conclusions: These results suggest efficacy and safety of tolvaptan for elderly patinets with severe heart failure, but also suggest effect for long term prognosis is limited.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect